Literature DB >> 9272910

Obstructive sleep apnoea syndrome: is the "half-night polysomnography" an adequate method for evaluating sleep profile and respiratory events?

F Fanfulla1, V Patruno, C Bruschi, C Rampulla.   

Abstract

Recently, to reduce the costs of polysomnography, split-night studies have been introduced into routine practice: the first part of the night is used to make the diagnosis of obstructive sleep apnoea syndrome (OSAS) and the second part to achieve an appropriate level of continuous positive airway pressure. Since this split-night protocol has not yet been validated by the comparison of polysomnographic pictures obtained in the first and second parts of the night, the aim of this study was to evaluate sleep profile and respiratory disturbances in the first part (PSG1) and second (PSG2) portion of a standard full-night polysomnographic examination (PSGtot) in a group of OSAS patients. Twenty nine consecutive OSAS patients, aged 54+/-10 yrs; body mass index (BMI) 40+/-6 kg x m(-2) (mean+/-SD values), were studied by separate analyses of PSG1, PSG2 and PSGtot. PSG1 was found to have a low sensitivity value (66%). A significant difference was found between apnoea-hypopnoea indices (AHI) recorded in PSG1, PSG2 and PSGtot (mean+/-SD, AHI1 33+/-27, AHI2 45+/-28, AHItot 40+/-25 events x h(-1), respectively; p<0.01). A strong correlation was observed between AHItot and AHI1 (r=0.89) and between AHItot and AHI2 (r=0.92), but a weaker correlation between AHI1 and AHI2 (r=0.66). These correlations became weaker when patients were subdivided into two different classes on the basis of disease severity. PSG1 was representative of PSGtot and similar to PSG2 only in those patients with rapid eye movement (REM) phase sleep in the first part of the night. We conclude that split-night protocols are not appropriate for evaluating sleep-disordered breathing in obstructive sleep apnoea syndrome patients when rapid eye movement phase sleep does not occur in the first part of the night.

Entities:  

Mesh:

Year:  1997        PMID: 9272910     DOI: 10.1183/09031936.97.10081725

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  The hypoxic ventilatory response and ventilatory long-term facilitation are altered by time of day and repeated daily exposure to intermittent hypoxia.

Authors:  David G Gerst; Sanar S Yokhana; Laura M Carney; Dorothy S Lee; M Safwan Badr; Tabarak Qureshi; Magalie N Anthouard; Jason H Mateika
Journal:  J Appl Physiol (1985)       Date:  2010-08-19

2.  Impact of repeated daily exposure to intermittent hypoxia and mild sustained hypercapnia on apnea severity.

Authors:  Sanar S Yokhana; David G Gerst; Dorothy S Lee; M Safwan Badr; Tabarak Qureshi; Jason H Mateika
Journal:  J Appl Physiol (1985)       Date:  2011-11-03

Review 3.  Intermittent hypoxia, respiratory plasticity and sleep apnea in humans: present knowledge and future investigations.

Authors:  Jason H Mateika; Ziauddin Syed
Journal:  Respir Physiol Neurobiol       Date:  2013-04-12       Impact factor: 1.931

4.  The impact of split-night versus traditional sleep studies on CPAP compliance.

Authors:  Jacob Collen; Aaron Holley; Christopher Lettieri; Anita Shah; Stuart Roop
Journal:  Sleep Breath       Date:  2009-08-28       Impact factor: 2.816

Review 5.  Intermittent hypoxia and respiratory plasticity in humans and other animals: does exposure to intermittent hypoxia promote or mitigate sleep apnoea?

Authors:  Jason H Mateika; Gunjan Narwani
Journal:  Exp Physiol       Date:  2008-12-05       Impact factor: 2.969

6.  The impact of arousal state, sex, and sleep apnea on the magnitude of progressive augmentation and ventilatory long-term facilitation.

Authors:  Ziauddin Syed; Ho-Sheng Lin; Jason H Mateika
Journal:  J Appl Physiol (1985)       Date:  2012-11-08

7.  The success rate of split-night polysomnography and its impact on continuous positive airway pressure compliance.

Authors:  Ahmed S BaHammam; Eiman ALAnbay; Nuha Alrajhi; Awad H Olaish
Journal:  Ann Thorac Med       Date:  2015 Oct-Dec       Impact factor: 2.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.